cemiplimab
sanofi,regeneron
['pivotal', 'cemiplimab', 'congrat', 'regeneron']
boom! another huge win for neoadjuvant io and for patients. neoadjuvant cemiplimab in cutaneous scc in ph2 trial: path cr= 51%; orr=68%; &gt;grade 3 ae=18% congrats to my friend and team for this pivotal advance. 
Physician Executive @providence; Head & Neck #Surgeon @provhealth; Member @chilesresearch focused on #immunotherapy. Tweets my own